Different immunotherapy approaches have been advanced, including the administration of therapeutic vaccines or exogenous cytokines to enhance the T cell number against tumor cells, the adoptive transfer of immune effector cells specific to tumor antigens, and nowadays, a variety of agonists of co-stimulatory receptors and ICPs that are applied to alleviate tumor-induced immunosuppressive action [62]. The gene discussed is AQP1; the disease is neoplasm.